[go: up one dir, main page]

MX2018005399A - Nuevo polipeptido con afinidad por pd-l1. - Google Patents

Nuevo polipeptido con afinidad por pd-l1.

Info

Publication number
MX2018005399A
MX2018005399A MX2018005399A MX2018005399A MX2018005399A MX 2018005399 A MX2018005399 A MX 2018005399A MX 2018005399 A MX2018005399 A MX 2018005399A MX 2018005399 A MX2018005399 A MX 2018005399A MX 2018005399 A MX2018005399 A MX 2018005399A
Authority
MX
Mexico
Prior art keywords
affinity
new polypeptide
present disclosure
binding polypeptide
relates
Prior art date
Application number
MX2018005399A
Other languages
English (en)
Other versions
MX382321B (es
Inventor
Wahlberg Elisabet
Gunneriusson Elin
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of MX2018005399A publication Critical patent/MX2018005399A/es
Publication of MX382321B publication Critical patent/MX382321B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a una clase de polipéptidos modificados que tienen una afinidad de unión por el ligando de muerte programada 1 (``PD-L1´´, por sus siglas en inglés), y proporciona un polipéptido de unión a PD-L1 que comprende la secuencia ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. La presente descripción también se refiere al uso de dicho polipéptido de unión a PD-L1 como un agente terapéutico, de pronóstico y/o de diagnóstico.
MX2018005399A 2015-10-30 2016-10-28 Nuevo polipéptido con afinidad por pd-l1. MX382321B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15192364 2015-10-30
EP16157154 2016-02-24
PCT/EP2016/076040 WO2017072280A1 (en) 2015-10-30 2016-10-28 New polypeptide having affinity to pd-l1

Publications (2)

Publication Number Publication Date
MX2018005399A true MX2018005399A (es) 2018-06-06
MX382321B MX382321B (es) 2025-03-13

Family

ID=57223674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005399A MX382321B (es) 2015-10-30 2016-10-28 Nuevo polipéptido con afinidad por pd-l1.

Country Status (15)

Country Link
US (1) US11155596B2 (es)
EP (2) EP3693378A1 (es)
JP (1) JP6810143B2 (es)
KR (1) KR102805258B1 (es)
CN (1) CN108290931A (es)
AU (1) AU2016347495B2 (es)
BR (1) BR112018007154A2 (es)
CA (1) CA3001264A1 (es)
ES (1) ES2773504T3 (es)
IL (1) IL258419B (es)
MX (1) MX382321B (es)
MY (1) MY187827A (es)
RU (1) RU2749110C2 (es)
WO (1) WO2017072280A1 (es)
ZA (1) ZA201802542B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383917B (es) 2014-11-25 2025-03-14 Bristol Myers Squibb Co Nuevos péptidos que se unen al ligando-1 de muerte programada (pd-l1) para formación de imagen.
JP6701217B2 (ja) 2014-11-25 2020-05-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 生物学的製剤の１８ｆ−放射性標識方法および組成物
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
EP3368557A1 (en) 2015-10-30 2018-09-05 Affibody AB New polypeptide
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
JP7016323B2 (ja) * 2016-06-01 2022-02-21 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
US11858960B2 (en) 2018-03-01 2024-01-02 Vrije Universiteit Brussel Human PD-L1-binding immunoglobulins
IT201800003470A1 (it) * 2018-03-13 2019-09-13 Biotecnomed Soc Consortile A Resp Limitata Peptide and uses thereof
CN110054666B (zh) * 2019-03-12 2021-01-01 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种用于抑制细胞pd-l1表达的多肽及其应用
US20220389066A1 (en) 2019-11-05 2022-12-08 Affibody Ab Polypeptides
EP3878858A1 (en) * 2020-03-11 2021-09-15 Affilogic Variants of sac7d and their use in cancer therapy
WO2023152144A1 (en) 2022-02-08 2023-08-17 Affibody Ab Protein z variants binding thymic stromal lymphopoietin and their medical use
WO2024034685A1 (ja) 2022-08-10 2024-02-15 興和株式会社 アフィボディミセル薬物複合体
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
WO2024227930A1 (en) 2023-05-04 2024-11-07 Affibody Ab New polypeptide
GB202318675D0 (en) 2023-12-06 2024-01-17 Oncopeptides Ab Novel polypeptides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
US20100285039A1 (en) * 2008-01-03 2010-11-11 The Johns Hopkins University B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
JP6440618B2 (ja) * 2012-10-05 2018-12-19 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
WO2014096163A1 (en) 2012-12-19 2014-06-26 Affibody Ab New polypeptides
WO2014140366A1 (en) * 2013-03-15 2014-09-18 Affibody Ab New polypeptides
CN103304638B (zh) 2013-07-08 2014-12-03 郑州大学 具有抗肿瘤活性的pd-l1亲和肽及其应用
SG10201808519VA (en) * 2013-12-17 2018-10-30 Genentech Inc Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
CN103936835B (zh) 2014-04-29 2016-03-30 郑州大学 具有抗肿瘤活性的靶向PD-L1IgV亲和肽D1
CN104086627B (zh) 2014-05-29 2016-06-08 郑州大学 具有抗肿瘤活性的PD-L1 IgV亲和肽S10
CN104761633B (zh) * 2015-03-25 2018-11-27 新乡学院 阻断猪pd-1/pd-l1通路的多肽及其应用
EP3368557A1 (en) 2015-10-30 2018-09-05 Affibody AB New polypeptide

Also Published As

Publication number Publication date
RU2018117862A3 (es) 2020-03-02
CA3001264A1 (en) 2017-05-04
JP6810143B2 (ja) 2021-01-06
EP3368545A1 (en) 2018-09-05
BR112018007154A2 (pt) 2018-11-06
RU2018117862A (ru) 2019-12-02
IL258419A (en) 2018-06-28
MX382321B (es) 2025-03-13
ES2773504T3 (es) 2020-07-13
RU2749110C2 (ru) 2021-06-04
KR20180072797A (ko) 2018-06-29
HK1255250A1 (en) 2019-08-09
IL258419B (en) 2021-10-31
AU2016347495A1 (en) 2018-05-10
US20180312565A1 (en) 2018-11-01
MY187827A (en) 2021-10-26
EP3693378A1 (en) 2020-08-12
JP2018537965A (ja) 2018-12-27
CN108290931A (zh) 2018-07-17
US11155596B2 (en) 2021-10-26
AU2016347495B2 (en) 2020-07-02
ZA201802542B (en) 2020-08-26
WO2017072280A1 (en) 2017-05-04
NZ741586A (en) 2021-11-26
KR102805258B1 (ko) 2025-05-12
EP3368545B1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
EP3957723A3 (en) Engineered ligase variants
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
MY198059A (en) Anti-ox40 antibodies and their uses
MY191944A (en) Binding proteins and methods of use thereof
SG10201909716RA (en) Modified j-chain
MY187971A (en) Antibody constructs for cd70 and cd3
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
MY191581A (en) Anti-pd-1 antibodies
MY188784A (en) Il-17a-binding polypeptides
SG10201803042PA (en) Anti-tim-3 antibodies
SG10201902326XA (en) Mk2 inhibitors and uses thereof
SG10201909629PA (en) Bioconjugates and uses thereof
BR112016029318A2 (pt) tratamento de mielomas
PH12022551462A1 (en) Ilt3-binding agents and methods of use thereof
SG10201907901XA (en) Antibodies, uses & methods
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
WO2018189661A3 (en) Methods and compounds for treating diabetes
PH12015501854A1 (en) Factor ix polypeptide formulations
PH12019502694A1 (en) Anti-trkb antibodies